On the stock market since 2021, it operates in the world of health and science. It has 17 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 28% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
Sales run at $4.6M a year. A small number, but proof the product has real buyers.
There is $9.1M in the vault; even if every debt were paid off, $9.1M would remain.
It pays out $0.15 per share each year — regular cash for whoever holds the stock.
A loss of $2.0M against $4.6M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, NNGRF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NNGRF is a high-risk stock — not yet profitable, and its future rides on its product catching on.